Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

TY - JOUR

T1 - Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

AU - King, Amber C.

AU - Weis, Taylor M.

AU - Derkach, Andriy

AU - Ball, Somedeb

AU - Pandey, Manu

AU - Mauro, Michael J.

AU - Goldberg, Aaron D.

AU - Stahl, Maximilian

AU - Famulare, Christopher

AU - Tallman, Martin S.

AU - Wang, Eunice S.

AU - Kuykendall, Andrew T.

AU - Rampal, Raajit K.

N1 - Funding Information: This study was supported by Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748); Raajit K. Rampal is supported by National Cancer Institute P01 CA108671 11. Funding Information: Amber C. King has received advisory/consulting fees from: Astellas, Abbvie, and Blueprint Medicines. Raajit K. Rampal has received consulting fees from: Constellation, Novartis, Kartos, Incyte, Celgene/BMS, Promedior, CTI, Blueprint, Stemline, Galecto, Pharmaessentia, Abbvie and research funding from Incyte, Constellation, Stemline, and Zentalis. Aaron D. Goldberg has served as a consultant or on advisory boards for AbbVie, Aptose, Astellas, Celgene, Daiichi Sankyo, and Genentech, has received research funding from AbbVie, Aptose, Cellularity, ADC Therapeutics, Aprea, AROG, Pfizer, and Prelude, and has received honoraria from Dava Oncology. Maximilian Stahl has consulted for the Boston Consulting Group. Michael J. Mauro has disclosed the following relationships: Novartis; consulting/advisory/research support (institution), Takeda; consulting/advisory/research support (institution), Sun Pharma/SPARC; research support (institution), Bristol Myers Squibb; consulting/advisory, Pfizer: consulting/advisory. Martin S. Tallman has disclosed the following relationships: Abbvie: Research Funding; Cellerant: Research Funding; Orsenix: Research Funding; ADC Therapeutics: Research Funding; BioSight: Membership on an entity's Board of Directors or advisory committees and Research Funding; Glycomimetics: Research Funding; Rafael: Research Funding; Amgen: Research Funding; Bioline rx: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; KAHR: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Delta Fly Pharma: Membership on an entity's Board of Directors or advisory committees; Oncolyze: Membership on an entity's Board of Directors or advisory Committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; UpToDate: Patents & Royalties. Eunice S. Wang has received consulting fees from Abbvie, Amgen, Astellas, BMS, Genentech, Gilead, GlaxoSmithKline, Jazz, Kite, Kura, Mana Therapeutics, Novartis, Stemline, Takeda; speaker roles for Astellas, Dava Oncology, Kura, Pfizer, Stemline; Data monitoring committees for Abbvie and Rafael Pharmaceuticals. Andrew T. Kuykendall has received consulting feels/honoraria from Blueprint, Novartis, Incyte, Celgene/BMS, Abbvie, CTI Biopharma, Pharmaessentia, Protagonist and research funding from Protagonist, Prelude, and Sierra. The remaining authors have no relevant disclosures. Funding Information: National Cancer Institute, Grant/Award Number: P01 CA108671 11; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center, Grant/Award Number: P30 CA008748 Funding information

PY - 2022/1/1

Y1 - 2022/1/1

UR - http://www.scopus.com/inward/record.url?scp=85118226517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118226517&partnerID=8YFLogxK

U2 - 10.1002/ajh.26381

DO - 10.1002/ajh.26381

M3 - Letter

C2 - 34674293

AN - SCOPUS:85118226517

SN - 0361-8609

VL - 97

SP - E7-E10

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -